12 Haa 3 maalmood, daraasad "The Lancet" oo lagu daabacay internetka, loogu talagalay CD30 - durugsan durugsan T -bukaanka lymfoma, rituximabkan, cyclophosphamide, doxorubicin iyo prednisone ( A + CHP ) Ka wanaagsan cyclophosphamide, doxorubicin, vincristine iyo prednisone () Garoocad ).
Steven Horwitz, MD, oo ka socda Xarunta Kansarka ee 'Memorial Sloan Kettering Cancer Center' oo ku taal magaalada New York iyo asxaabtiisuba waxay sameeyeen laba indhoole, xakamaynta xakamaynta, wajiga 3-daraasad firfircoon oo ku lug leh bukaanada 452 oo ka kala yimid 132 goobood oo ku yaal 17 dal. Bukaanadani CD30-lymphoma peripheral per-peripheral T-cell lymphoma iyaga oo aan daaweyn hore helin. Bukaannada qaba 1: 1 saamiga qoondaynta aan kala sooca lahayn, ayaa qaata A + CHP ama CHOP, waara 6, ama. 8 th 21 waa wareegga maalinta.
Cilmi baarayaashu waxay ogaadeen in badbaadada dhexdhexaad-la'aanta (PFS) ee kooxda A + CHP iyo kooxda CHOP ay ahaayeen 48.2 iyo 20.8 bilood, siday u kala horreeyaan. Dhacdooyinka saameynaha ayaa lamid ahaa labada koox, oo ay kujiraan qandhada neerfaha (18% iyo 15%, siday u kala horreeyaan) iyo neuropathy durugsan (52% iyo 55%, siday u kala horreeyaan). Dhacdooyinka halista ah ee dhimashada ayaa ka dhacay 3% iyo 4% bukaannada, siday u kala horreeyaan.
In the CHP to add this cetuximab can improve progression-free and overall survival without increasing toxicity, the study supports the A + CHP for many CD30 positive outer peripheral T new standard treatment for qanjiro bukaanka.
